Ampreloxetine for Neurogenic Orthostatic Hypotension in MSA
Neurology Minute
Dr. Elizabeth Coon and Dr. Lucy Norcliffe-Kaufmann discuss the mechanism-based therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, highlighting recent clinical trial results and future directions. Show citation: Freeman R, Kaufmann H, Biaggioni I, et al. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial. Neurology. 2026;107(3):e218284. doi:
info_outline
Sex Differences in Levodopa Pharmacokinetics in Early Parkinson Disease
Neurology Minute
Dr. Margarita Fedorova explores sex-related differences in the pharmacokinetics of levodopa among levodopa-naïve patients with PD and evaluates their relationships with levodopa-related complications. Show citation: Conti V, De Bellis E, Corbi G, et al. Sex differences in levodopa pharmacokinetics in early Parkinson's disease: implications on levodopa-related complications. Front Pharmacol. 2026;17:1748932. Published 2026 Apr 7. doi:
info_outline
Psychiatric Comorbidities in Epilepsy - Part 2
Neurology Minute
In part two of this series, Dr. Halley Alexander and Dr. Heidi Munger Clary discuss the steps to take if you are screening for a psychiatric comorbidity and the results indicate that someone may be positive for depression, anxiety, or another condition. Show citations: Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63(2):316-334. doi: Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017...
info_outline
August 2026 President Spotlight: How We’re Working with the AMA
Neurology Minute
In the August episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost highlight how the AAN’s growing representation within the AMA strengthens the voice of neurology. Stay informed by watching the .
info_outline
Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 2
Neurology Minute
In part two of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the FENhance 1 and 2 trials looking at fenebrutinib in relapsing MS. For more information, please read about the abstract that was presented at the . Read more about the .
info_outline
Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 1
Neurology Minute
In part one of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the fenebrutinib trial and highlight the key takeaways that healthcare providers should be aware of. For more information, please read about the abstract that was presented at the . Read more about the .
info_outline
Psychiatric Comorbidities in Epilepsy - Part 1
Neurology Minute
In part one of this series, Dr. Halley Alexander and Dr. Heidi Munger Clary discuss the best methods for screening patients with epilepsy in a clinical setting. Show citations: Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63(2):316-334. doi: Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update. Neurology. 2018;91(18):829-836. doi:
info_outline
2026 International Conference on Functional Neurological Disorder - Part 2
Neurology Minute
In the second episode of this series, Dr. Dara Albert and Dr. Jon Stone discuss the future of FND and the innovative topics presented at the conference.
info_outline
Exploring Military Sexual Trauma and Migraine Among US Veterans - Part 2
Neurology Minute
In part two of this series, Dr. Stacey Clardy and Dr. John Ney discuss what neurologists should do differently after reading this article. Show citation: Ney J, Fenton B, Grinberg AS, et al. Association of Military Sexual Trauma With Migraine and Migraine-Related Health Care Utilization Among Post-9/11 US Veterans. Neurol Clin Pract. 2026;16(3):e200618. doi:
info_outline
2026 International Conference on Functional Neurological Disorder - Part 1
Neurology Minute
In the first episode of this series, Dr. Dara Albert and Dr. Jon Stone emphasize the main takeaway from this year's conference that should be taught to residents.
info_outlineDr. Stacey Clardy discusses methylenetetrahydrofolate reductase (MTHFR) in this lab minute.
Show transcript:
Dr. Stacey Clardy:
Hi, this is Stacey Clardy from the Salt Lake City VA in the University of Utah. Let's do a lab minute today on MTHFR. This one just simply will not go away. This is one of those topics where a huge amount of patient anxiety is inversely proportional to the utility of a test.
So MTHFR is methylenetetrahydrofolate reductase. It's the enzyme that helps generate five methyltetrahydrofolates supporting remethylation of homocysteine to methionine. That biochemistry does matter because the clinical leap that often follows is the problem.
So the common polymorphisms of MTHFR are C677T and A1298C. They are widespread in the general population. A recurring misunderstanding is that ordering MTHFR genotyping in a thrombophilia evaluation or as a catchall explanation for you name it, migraines, neuropathy, psychiatric symptoms, nondescript inflammation, is going to give you the answer.
The best evidence-based guidance is that MTHFR polymorphism testing has minimal clinical utility and should not be ordered routinely, particularly not as part of a thrombophilia evaluation.So what do we do when a patient arrives with one of these MTHFR results and they are concerned? I try to translate into what actually matters clinically. If there is a concern for thrombotic risk or a documented thrombotic risk event, I focus on established thrombophilias and clinical risk factors and not common MTHFR isolated variants.
Now, if the concern is folate metabolism and homocystine, well, we can actually measure those nutritional markers and homocystine. And so if homocystine is elevated, the next thing I'll do is consider the context.
And if their folate is low or if one of their B vitamins is low, I replace it rather than building a medical mythology around a genotype that's not going to change the management for most patients.
So that's an approach and an update to MTHFR. I hope it's helpful. This is Stacey Clardy, until next time.